Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
Immune Checkpoint Inhibitors (ICIs) are well recognized as a major immune treatment modality for multiple types of solid cancers. However, for colorectal cancer (CRC), ICIs are only approved for the treatment of Mismatch-Repair-Deficient and Microsatellite Instability-High (dMMR/MSI-H) tumors. For t...
Main Authors: | Nicolas Huyghe, Elena Benidovskaya, Philippe Stevens, Marc Van den Eynde |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/9/2241 |
Similar Items
-
The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer
by: Kai Ding, et al.
Published: (2023-12-01) -
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
by: David J. Hermel, et al.
Published: (2019-01-01) -
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
by: Chang Woo Kim, et al.
Published: (2021-09-01) -
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
by: Julie Lang, et al.
Published: (2022-11-01) -
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
by: Sacha Gnjatic, et al.
Published: (2017-05-01)